Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Payables (2018 - 2025)

Historic Payables for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $4.2 million.

  • China SXT Pharmaceuticals' Payables rose 1312.93% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 1312.93%. This contributed to the annual value of $3.6 million for FY2025, which is 10534.23% up from last year.
  • As of Q3 2025, China SXT Pharmaceuticals' Payables stood at $4.2 million, which was up 1312.93% from $3.6 million recorded in Q1 2025.
  • China SXT Pharmaceuticals' Payables' 5-year high stood at $4.2 million during Q3 2025, with a 5-year trough of $1.5 million in Q1 2023.
  • Moreover, its 5-year median value for Payables was $3.5 million (2021), whereas its average is $3.2 million.
  • Its Payables has fluctuated over the past 5 years, first plummeted by 5621.73% in 2023, then soared by 10534.23% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Payables (Quarter) stood at $3.4 million in 2021, then dropped by 3.15% to $3.3 million in 2022, then grew by 7.26% to $3.5 million in 2023, then grew by 6.66% to $3.8 million in 2024, then rose by 13.13% to $4.2 million in 2025.
  • Its Payables stands at $4.2 million for Q3 2025, versus $3.6 million for Q1 2025 and $3.8 million for Q3 2024.